Merck KGaA announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), for its application to broaden the use of the targeted cancer therapy Erbitux® (cetuximab) to an enlarged lab
By the time you're done with this area you should accept a acceptable abstraction of the science abaft abscess and feel assured in how you would like to proceed.
Monday, June 2, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment